产品资料

NCI-H23细胞

如果您对该产品感兴趣的话,可以
产品名称: NCI-H23细胞
产品型号: NCI-H23
产品展商: HZbscience
产品文档: 无相关文档

简单介绍

NCI-H23细胞应如何避免细胞污染,细胞污染的种类可分成**、酵母菌、霉菌、病毒和霉浆菌。主要的污染原因为无菌操作技术不当、操作室环境不佳、污染之血清和污染之细胞等。严格之无菌操作技术、清洁的环境、与品质良好之细胞来源和培养基配制是减低污染之*好方法。NCI-H23细胞何时须更换培养基?视细胞生长密度而定,或遵照细胞株基本数据上之更换时间,按时更换培养基即可。


NCI-H23细胞  的详细介绍

NCI-H23细胞

细胞形态: 上皮样

是否是肿瘤细胞: 1

物种来源: 人

器官来源: 肺

生长状态: 贴壁生长

ATCC Number: CRL-5800™

数量: 大量

相关**: 非小细胞肺癌

运输方式: 冻存运输

年限: 51 years

Designations: NCI-H23 [H23]

NCI-H23细胞Depositors: AF Gazdar, JD Minna

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial


Source: Organ: lung

Disease: adenocarcinoma; non-small cell lung cancer

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: NCI-H23细胞The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.

Oncogene: myc +; src +; abl +; erb +; ras +; sis -

DNA Profile (STR): Amelogenin: X

CSF1PO: 10

D13S317: 12

D16S539: 11

D5S818: 12,13

D7S820: 9,10

THO1: 6

TPOX: 8,9

vWA: 16,17

Age: 51 years

Gender: male

Ethnicity: Black

Comments: NCI-H23细胞This line was derived from a lung cancer obtained from a patient prior to therapy.

The cells carry the K-ras 12 mutation, and there is a mutation in codon 246 (ATC -> ATG, isoleucine -> methionine) of the p53 gene.

There is expression of C-myc, L-myc, v-src, v-abl, v-erb B, c-raf 1, Ha-ras, Ki-ras and N-ras RNAs.

The cells express heterogeneous mRNA expression for PDGF A and B chain, transforming growth factor alpha and beta and the epidermal growth factor receptor (EGFR).

NCI-H23 exhibits a high degree of c-myc DNA amplification (20-fold) but no detectable amplification of c-myc RNA.

The cells stain positive for keratins 5+8 and 18 and vimentin but are negative for neurofilament.

NCI-H23 cells are L-dopa decarboxylase-negative.

They have a reported colony forming efficiency of 9.7% in soft agarose.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended

Medium Renewal: Every 2 to 3 days

Remove spent medium, and add fresh 0.25% trypsin, 0.03% EDTA solution for 2 to 3 minutes at room temperature.

Remove the trypsin and incubate the flask at 37C for 5 to 10 minutes or until the cells detach.

Add fresh medium, aspirate and dispense into new flasks.

Preservation: NCI-H23细胞Culture medium, 95%; DMSO, 5%

Doubling Time: 38 hrs

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

References: 1805: Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201

1806: Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494

22403: Mitsudomi T, et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7: 171-180, 1992. PubMed: 1311061

22434: Brower M, et al. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 46: 798-806, 1986. PubMed: 3940644

22465: Broers JL, et al. Spontaneous changes in intermediate filament protein expression patterns in lung cancer cell lines. J. Cell Sci. 91: 91-108, 1988. PubMed: 2473086

22868: Forsberg K, et al. Expression of functional PDGF beta receptors in a human large-cell lung- carcinoma cell line. Int. J. Cancer 53: 556-560, 1993. PubMed: 8382192

23036: Gazdar AF, et al. NCI-H23细胞Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res. 40: 3502-3507, 1980. PubMed: 6108156

23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..

24389: . . Lung Cancer 4: 155-161, 1988.

沪公网安备 31011702004356号